SLE is a dubious disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological checks.
The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL accompanied by SLE. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.